Association of human leukocyte antigen groups with oral mucositis in patients undergoing bone marrow transplantation

2020 ◽  
Author(s):  
Ayse Nur Tufan ◽  
Fatma Savran Oguz ◽  
Fatih Tufan ◽  
Cigdem Kekik ◽  
Fatma Bilgin Tarakci ◽  
...  
Keyword(s):  
Stem Cell ◽  
Human Leukocyte Antigen ◽  
Oral Mucositis ◽  
Conditioning Regimen ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
Stem Cell Source ◽  
Hematopoetic Stem Cell ◽  
Hla Phenotype

Abstract Background: Oral mucositis (OM) after hematopoetic stem cell transplantation (HSCT) may lead to toxicity that impair quality of life. Associations between some diseases and human leukocyte antigen (HLA) groups have been long recognized. A genetic contribution as the association of HLA groups with OM after HSCT, has not been reported to date. We aimed to assess whether an association of HLA phenotype and OM after allogeneic HSCT exists.Methods: This was a prospective observational study in which OM was assessed with clinical questioning and examination. Association of OM with gender, age, HLA phenotypes, diagnosis, conditioning regimen, stem cell source, engraftment times, and complications was investigated.Results: 45 patients were enrolled. All the patients with HLA-B44 phenotype developed mild OM, while all patients with HLA-DR15 phenotype developed severe OM. HLA-A23, HLA-B21, HLA-B44, HLA-DR15, and HLA-DR11 were associated with shorter OM duration. HLA-A26 and HLA-B52 were associated with longer OM duration. Myeloablative conditioning regimen and longer duration of neutropenia were associated with longer OM duration. Regression analysis revealed HLA-B44 and HLA-DR11 as independent factors associated with milder OM.Conclusion: We identified that some HLA alleles correlated with OM severity and duration. These findings may facilitate predicting risk of morbidity and may provide incorporation of individualized preventive and treatment approaches.

Significance of a Single Human Leukocyte Antigen Mismatch on the Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation from Related Donors Using the Mexican Schedule.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5182-5182
Author(s):  
Guillermo J. Ruiz-Arguelles ◽  
Briceida López-Martínez ◽  
Carlos Manzano ◽  
J. D. Gómez-Rangel
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Human Leukocyte Antigen ◽  
Cell Transplantation ◽  
Chronic Gvhd ◽  
Conditioning Regimen ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
Nonmyeloablative Stem Cell Transplantation ◽  
Number Of Patients

Abstract The Mexican approach was used to conduct nonmyeloablative stem cell transplantation (SCT) in patients with various malignant and non-malignant hematologic diseases. Patients received a modified, low-intensity conditioning regimen, which included oral busulphan 4 mg/kg on Days −6 and −5, IV cyclophosphamide 350 mg/m2 on Days −4, −3, and −2, IV fludarabine 30 mg/m2 on Days −4, −3, and −2, oral cyclosporine A 5 mg/kg twice daily staring on Day −1 (continuing until Day 180), and IV methotrexate 5 mg/m2 on Days +1, +3, +5, and +11. Allografts were prospectively performed in 58 patients using sibling donors that were either human leukocyte antigen (HLA) identical (6/6) or compatible with 1 mismatch (5/6). In allografts where the donor was an HLA identical sibling (n = 40), the median overall survival was 33 months compared to 8 months when the donor was an HLA compatible sibling (n = 18; P <.01). The 52-month survival was 47% versus 38% in patients receiving allografts from HLA-identical donors and HLA-compatible donors, respectively. The prevalence of acute graft-versus-host-disease (GVHD) was 57% versus 38%, the prevalence of chronic GVHD was 25% versus 11%, and the relapse rate was 45% versus 55% in patients receiving allografts from HLA-identical donors and HLA-compatible donors, respectively. Two patients failed to engraft; both were 5/6 matches. Despite a trend toward less favorable results in patients allografted from HLA compatible (5/6) siblings, most differences in outcome were not significant, likely due to the small number of patients in the study. These data suggest that nonmyeloablative SCT using the Mexican approach may be a valid option for individuals with either an HLA identical or HLA compatible sibling donor.

Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen–Identical Siblings Versus Human Leukocyte Antigen–Allelic–Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy

2006 ◽  
Vol 24 (36) ◽  
pp. 5695-5702 ◽  
Author(s):  
Ibrahim Yakoub-Agha ◽  
Florence Mesnil ◽  
Mathieu Kuentz ◽  
Jean Michel Boiron ◽  
Norbert Ifrah ◽  
...  
Keyword(s):  
Stem Cell ◽  
Human Leukocyte Antigen ◽  
Myeloid Leukemia ◽  
Hematologic Malignancy ◽  
Human Leukocyte ◽  
Positive Serology ◽  
Leukocyte Antigen ◽  
Donor Type ◽  
Unrelated Donors ◽  
Standard Risk

Purpose To investigate the influence of donor type (human leukocyte antigen [HLA] -identical sibling donor versus HLA-A–, HLA-B–, HLA-Cw–, HLA-DRB1–, and HLA-DQB1–identical unrelated donors, or so-called 10/10) on the outcome of patients who underwent allogeneic stem-cell transplantation (alloSCT), adjusting for other prognostic factors, in patients with standard-risk hematologic malignancy. Patients and Methods Between March 2000 and January 2003, we prospectively investigated the outcome of 236 consecutive patients with standard-risk malignancy from 12 French centers. Fifty-five patients underwent alloSCT from an unrelated HLA-identical donor at the allelic level, whereas 181 patients received an alloSCT from an HLA-identical sibling. Diagnoses included acute leukemia (n = 175), chronic myeloid leukemia (n = 43), and myelodysplastic syndrome (MDS; n = 18). All patients received unmodified marrow graft following myeloablative conditioning with cyclophosphamide and total-body irradiation. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and short-course methotrexate in all patients. Results In multivariable analysis, overall survival and transplantation-related mortality were adversely influenced by recipient cytomegalovirus (CMV) -positive serology, age of donor older than 37 years, and the occurrence of acute grade ≥ II GVHD. Event-free survival rates were lower for patients with recipient CMV-positive serology. Acute grades II to IV GVHD rates were higher for patients with chronic myeloid leukemia (CML). No factor was found to influence either relapse or acute grades III to IV GVHD. The effect of donor type was nonsignificant for all criteria. Conclusion In patients with standard-risk malignancy, transplantation from unrelated HLA-allellically matched donors led to outcomes similar to those from HLA-identical sibling donors.

Sign in / Sign up

Export Citation Format

Share Document